Zosano Pharma (ZSAN) receives FDA comments and recommendations to proposed pharmacokinetic study protocol for Qtrypta

April 13, 2021 4:40 PM EDT
Get Alerts ZSAN Hot Sheet
Price: $0.80 -4.76%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Zosano Pharma (NASDAQ: ZSAN) disclosed:

On April 12, 2021, Zosano Pharma Corporation (the “Company”) received U.S. Food and Drug Administration comments and recommendations to the Company’s proposed pharmacokinetic (PK) study protocol for Qtrypta™. Based on these comments, the Company plans to make the recommended changes to the study protocol and proceed with finalizing the protocol, study site selection and study conduct.




Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

FDA